摘要
目的:探讨重组人干扰素α-2a栓治疗宫颈人乳头瘤病毒(HPV)亚临床感染的疗效及安全性。方法:选择106例宫颈HPV亚临床感染患者,随机分为实验组与对照组,每组患者各53例。实验组予以重组人干扰素α-2a栓阴道塞入,每次1枚,隔日1次,连用15次为1个疗程;对照组予以双唑泰栓阴道塞入,每次1枚,隔日1次,亦连用15次。观察两组患者的治疗效果及不良反应情况。结果:治疗1个疗程后,实验组患者治疗效果明显优于对照组(χ2=3.98,P<0.05),两组患者不良反应情况比较无明显差异(χ2=0.14,P>0.05)。结论:重组人干扰素α-2a栓治疗宫颈HPV亚临床感染具有使用方便、疗效显著、不良反应少等优点。
Objectives： To explore the effect and safety of recombinant human interferon α-2a suppository in the treatment of subclinical infection of human papilloma virus （HPV）.Method： 106 patients with subclinical infection of HPV were randomly divided into experimental group and control group,with 53 cases in each group.The patients in the experimental group were put one recombinant human interferon α-2a suppository into the vagina,once every 2 days,15 times as one course of treatment.The patients in the control group were put one metronidazole,clotrimazole and chlorhexidine acetate suppository into the vagina,once every 2 days,15 times as one treatment course.The 2 groups were observed in terms of the effects and adverse reactions.Results： After one course of treatment,the curative effect of patients in experimental group was significantly better than that in the control group （x2 =3.98,P ＜ 0.0）,the adverse reactions of the two groups were not statistically different （x2 =0.14,P ＞ 0.05）.Conclusion： The recombinant human interferon α-2a suppository was convenient,effective,and having less adverse reactions in the treatment of subclinical infection of human papilloma virus （HPV）.
出处
《中国性科学》
2014年第3期27-28,共2页
Chinese Journal of Human Sexuality
关键词
重组人干扰素α-2a栓
宫颈人乳头瘤病毒
亚临床感染
疗效
Recombinant human interferon α-2a suppository
Human papilloma virus （HPV）
Subclinical infection
Curative effect
